The North America Microbiome Diagnostics Market would witness market growth of 16.9% CAGR during the forecast period (2023-2030).
The US market dominated the North America Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $157,641.6 Thousands by 2030. The Canada market is exhibiting a CAGR of 19.5% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 19.1% during (2023 - 2030).
It is increasingly integrated into clinical practice, particularly in gastroenterology, oncology, immunology, dermatology, and women’s health. Clinicians utilize microbiome diagnostics to aid in disease diagnosis, risk assessment, treatment selection, and monitoring of therapeutic responses. For example, in gastroenterology, it helps identify microbial biomarkers associated with inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and colorectal cancer, guiding personalized treatment strategies and dietary interventions. In dermatology, it is used to study the skin microbiome and its role in dermatological conditions such as acne, eczema, and psoriasis, informing skincare interventions and therapeutic approaches. The adoption of microbiome diagnostics in clinical settings is driven by the need for more precise and personalized healthcare solutions tailored to individual patient characteristics and microbial profiles.
Additionally, it is widely utilized in research laboratories to investigate microbiome-host interactions, disease mechanisms, and therapeutic targets. Academic institutions, biotechnology companies, and pharmaceutical firms invest in microbiome research initiatives, leveraging microbiome diagnostics to drive innovation in drug discovery, biomarker identification, and therapeutic development. Researchers utilize microbiome diagnostics to study microbial communities’ composition, diversity, and function in various disease states, environmental contexts, and experimental models. It enables researchers to unravel the complex relationships between microbial communities and host physiology, paving the way for discoveries and breakthroughs in microbiome research.
Mexico’s pharmaceutical sector’s growth can provide financial resources and infrastructure support for clinical trials and research initiatives focused on microbiome-based interventions. The pharmaceutical sector in Mexico is divided into patented medicines, which represent 51 percent of the market by value, generics, which represent 35 percent, and over-the-counter products, which represent the remaining 14 percent. As the pharmaceutical sector expands in Mexico, there may be a growing interest in microbiome-based therapeutics for various diseases and conditions. Hence, the increasing investments in the healthcare sector and the rising pharmaceutical industry in the region are propelling the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $157,641.6 Thousands by 2030. The Canada market is exhibiting a CAGR of 19.5% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 19.1% during (2023 - 2030).
It is increasingly integrated into clinical practice, particularly in gastroenterology, oncology, immunology, dermatology, and women’s health. Clinicians utilize microbiome diagnostics to aid in disease diagnosis, risk assessment, treatment selection, and monitoring of therapeutic responses. For example, in gastroenterology, it helps identify microbial biomarkers associated with inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and colorectal cancer, guiding personalized treatment strategies and dietary interventions. In dermatology, it is used to study the skin microbiome and its role in dermatological conditions such as acne, eczema, and psoriasis, informing skincare interventions and therapeutic approaches. The adoption of microbiome diagnostics in clinical settings is driven by the need for more precise and personalized healthcare solutions tailored to individual patient characteristics and microbial profiles.
Additionally, it is widely utilized in research laboratories to investigate microbiome-host interactions, disease mechanisms, and therapeutic targets. Academic institutions, biotechnology companies, and pharmaceutical firms invest in microbiome research initiatives, leveraging microbiome diagnostics to drive innovation in drug discovery, biomarker identification, and therapeutic development. Researchers utilize microbiome diagnostics to study microbial communities’ composition, diversity, and function in various disease states, environmental contexts, and experimental models. It enables researchers to unravel the complex relationships between microbial communities and host physiology, paving the way for discoveries and breakthroughs in microbiome research.
Mexico’s pharmaceutical sector’s growth can provide financial resources and infrastructure support for clinical trials and research initiatives focused on microbiome-based interventions. The pharmaceutical sector in Mexico is divided into patented medicines, which represent 51 percent of the market by value, generics, which represent 35 percent, and over-the-counter products, which represent the remaining 14 percent. As the pharmaceutical sector expands in Mexico, there may be a growing interest in microbiome-based therapeutics for various diseases and conditions. Hence, the increasing investments in the healthcare sector and the rising pharmaceutical industry in the region are propelling the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Market Report Segmentation
By Application- Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
- Research Application
- Reagents & Kits
- Instruments
- Fecal
- Saliva
- Skin
- Others
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Others
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. North America Microbiome Diagnostics Market by Application
Chapter 6. North America Microbiome Diagnostics Market by Product
Chapter 7. North America Microbiome Diagnostics Market by Sample
Chapter 8. North America Microbiome Diagnostics Market by Technology
Chapter 9. North America Microbiome Diagnostics Market by End User
Chapter 10. North America Microbiome Diagnostics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Methodology
LOADING...
